Design Therapeutics Financials
| DSGN Stock | USD 5.62 0.05 0.90% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 23.87 | 29.5764 |
|
|
Investors should never underestimate Design Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Design Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Design Therapeutics.
Net Income |
|
Design | Select Account or Indicator |
Understanding current and past Design Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Design Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Design Therapeutics' assets may result in an increase in income on the income statement.
Design Therapeutics Stock Summary
Design Therapeutics competes with Monte Rosa, Werewolf Therapeutics, Ikena Oncology, Stoke Therapeutics, and Achilles Therapeutics. Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. Design Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 51 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US25056L1035 |
| CUSIP | 25056L103 |
| Location | California; U.S.A |
| Business Address | 6005 Hidden Valley |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.designtx.com |
| Phone | 858 293 4900 |
| Currency | USD - US Dollar |
Design Therapeutics Key Financial Ratios
| Return On Equity | -0.18 | ||||
| Price To Sales | 22,642 X | ||||
| Gross Profit | (48.61 M) | ||||
| EBITDA | (66.33 M) | ||||
| Net Income | (66.86 M) |
Design Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Design Therapeutics's current stock value. Our valuation model uses many indicators to compare Design Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Design Therapeutics competition to find correlations between indicators driving Design Therapeutics's intrinsic value. More Info.Design Therapeutics is rated # 2 in return on equity category among its peers. It also is rated # 2 in return on asset category among its peers . At this time, Design Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Design Therapeutics' earnings, one of the primary drivers of an investment's value.Design Therapeutics Systematic Risk
Design Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Design Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Design Therapeutics correlated with the market. If Beta is less than 0 Design Therapeutics generally moves in the opposite direction as compared to the market. If Design Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Design Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Design Therapeutics is generally in the same direction as the market. If Beta > 1 Design Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Design Therapeutics Thematic Clasifications
Design Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Today, most investors in Design Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Design Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Design Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Design Therapeutics November 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Design Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Design Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Design Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Design Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Design Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.89 | |||
| Information Ratio | 0.0413 | |||
| Maximum Drawdown | 35.31 | |||
| Value At Risk | (8.21) | |||
| Potential Upside | 9.61 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.